About
AWI Leadership Board
Resources by Tumor Type
Provider Resources
Care Step Pathways
Continuing Education
Provider Toolkits
Healthcare Disparities
Primer
Videos
ctDNA Testing for Response Monitoring
Facebook Provider Community
News
Patient/Caregiver Resources
Patient Action Plans
Caregiver Resource
Options for Stage IV Melanoma
Options for Stage III Melanoma
Options for Stage II Melanoma
Non-Invasive Evaluation Tools (Melanoma)
ctDNA Testing Handout
International Resources
Australia
Canada
France
Germany
Italy
Portugal
Spain
UK
Videos
HCP Videos
Patient Videos
About
AWI Leadership Board
Resources by Tumor Type
Provider Resources
Care Step Pathways
Continuing Education
Provider Toolkits
Healthcare Disparities
Primer
Videos
ctDNA Testing for Response Monitoring
Facebook Provider Community
News
Patient/Caregiver Resources
Patient Action Plans
Caregiver Resource
Options for Stage IV Melanoma
Options for Stage III Melanoma
Options for Stage II Melanoma
Non-Invasive Evaluation Tools (Melanoma)
ctDNA Testing Handout
International Resources
Australia
Canada
France
Germany
Italy
Portugal
Spain
UK
Videos
HCP Videos
Patient Videos
The AIM with Immunotherapy Initiative – Home
›
Forums
›
Intralesional immunotherapy
›
Other
This forum is empty.
Oh, bother! No topics were found here.
You must be logged in to create new topics.
Log In
Username:
Password:
Keep me signed in
Log In
Login
Log In
Username:
Password:
Keep me signed in
Log In
Register
Lost Password
Latest Activity
New BRAF/MEK inhibitors coming to market
topic by
Anonymous
March 1
in
Dosing and administration
Adjuvant Immunotherapy in stage IIIA patients
topic by
Anonymous
March 1
in
Expectations for therapy
Influenza and Tamiflu and Immunotherapy
reply by
Anonymous
February 25
in
Other
ASCO/NCCN guidlines now out
reply by
Anonymous
February 23
in
Side-effect management
hepatotoxicity
reply by
Anonymous
February 23
in
Side-effect management
© 2022 AIM with Immunotherapy. All rights reserved.
